title: [Treatment of hormonal refractory metastatic prostate cancer].
abstract: Hormonal refractory metastatic prostate cancer is a fatal disease with a poor prognosis. Treatment options are palliative with second line anti-hormonal, estrogens and prednisolon. When palliation is the goal, the side effects have to be carefully considered. Local radiotherapy has an effective pain relieving effect, and can be repeated. Chemotherapy with docetaxel and prednisolon is indicated in patients with symptomatic metastatic disease. Newer options with immunotherapy and designed molecules have not yet proven effective. Pain and anemia are significant symptoms and should be treated in a multidisciplinary setting.
authors.affiliation: Herlev Hospital, Onkologisk Afdeling, Herlev. lisa.sengelov@dadlnet.dk
authors.forename: Lisa
authors.initials: L
authors.lastname: Sengeløv
authors.forename: Ole Peter
authors.initials: OP
authors.lastname: Klarskov
authors.forename: Stellan
authors.initials: S
authors.lastname: Karlsson
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007167:Immunotherapy; D008297:Male; D010166:Palliative Care; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary / Q000628:therapy
chemical_list: D018931:Antineoplastic Agents, Hormonal